C
linical proteinuria, defined as dipstick-positive proteinuria, is a risk factor for end-stage renal disease (1), c a rdiovascular disease (2), congestive heart f a i l u re (CHF) (3), and mortality (4,5) in patients without CHF. ACE inhibitors reduce proteinuria in both diabetic and nondiabetic patients (6,7) without CHF. The effect of ACE inhibitors on pro t e i n u r i a in patients with CHF, and specifically whether ACE inhibitors prevent pro t e i nuria from developing in these patients, has not been studied. The Studies of Left Ve ntricular Dysfunction (SOLVD) consisted of two randomized double-blind placeboc o n t rolled trials in which enalapril significantly reduced cardiac and all-cause m o rtality in 2,569 patients with chro n i c CHF who were followed for a mean of 41.4 months and in which enalapril significantly reduced the risk of development of CHF in another 4,228 asymptomatic patients with left ventricular (LV) dysfunction. A total of 970 patients who indicated a history of diabetes at baseline were included in these studies. Urine pro t e i n was measured at baseline and every 4 months for up to 2 years in the SOLV D . These data were analyzed to determine the p revalence of proteinuria at baseline and to d e t e rmine whether ACE inhibitors pre v e n t p roteinuria in patients with CHF.
RESEARCH DESIGN AND M E T H O D S -
A full description of the S O LVD trials has been published elsewhere (8,9). In brief, patients with a cardiac ejection fraction of 0.35 who were either symptomatic or asymptomatic were re c ruited for the SOLVD treatment or prevention trials, re s p e c t i v e l y. They were randomly assigned to receive either enalapril or placebo in 83 hospitals linked to 23 centers in the U.S., Canada, or Belgium, in a double-blind fashion. Patients randomized to enalapril in the treatment trial initially received a dose of 2.5 or 5 mg twice daily on the basis of the patient' s clinical condition. In the prevention trial, the initial dose of enalapril was 2.5 mg twice daily. In both trials, the dose was titrated up to a maximum of 10 mg twice daily. After randomization, all patients were examined after 2 weeks, 6 weeks, and 4 months and then every 4 months there a f t e r. Urine dipstick tests for protein were perf o rmed at baseline and at every follow-up visit for up to 2 years. Proteinuria was measured with locally available dipsticks. Clinical pro t e i nuria was defined as 2 p rotein on dipstick. The definition of diabetes was based on a self-re p o rted history of diabetes at the time of entry into the study.
The combined dataset of the SOLV D p revention and treatment trials was used for this analysis. Baseline characteristics O B J E C T I V E -Clinical proteinuria is a risk factor for both end-stage renal disease and cardiovascular disease. The prevalence of clinical proteinuria, its correlates and predictive value, and the effect of ACE inhibitors in preventing clinical proteinuria in diabetic and nondiabetic patients with left ventricular (LV) dysfunction are unknown.
RESEARCH DESIGN AND METHODS -The Studies of Left Ventricular Dysfunction ( S O LVD) trials were analyzed to determine the baseline distribution of clinical proteinuria and related cardiovascular risk factors, the effect of baseline proteinuria on the risk of hospitalization for congestive heart failure (CHF) and mort a l i t y, and the effect of enalapril in pre v e n t i n g new clinical pro t e i n u r i a .
R E S U LT S -A total of 5,487 out of 6,797 SOLVD participants (81%) were assessed for proteinuria at baseline. A total of 177 patients (3.2%) had baseline proteinuria. These patients had significantly higher systolic (137 vs. 125 mmHg, P 0.001) and diastolic (83 vs. 77 mmHg, P 0.001) blood pre s s u re levels, a higher prevalence of diabetes (41 vs. 18%, P 0.001), a lower ejection fraction (26.2 vs. 27.3%, P 0. 
Enalapril in diabetic patients in the SOLVD
(including age, sex, diabetes status, NYHA class, blood pre s s u re level, and tre a t m e n t assignment) were compared for patients who did and did not have a urine dipstick re c o rded at baseline and for patients with and without clinical proteinuria at baseline (by using a t test for continuous variables and a 2 test for categorical variables). Ti m e to development of proteinuria, first hospitalization for CHF, and death were defined as outcomes for the current analyses. The Cox pro p o rtional hazards model (10) was used to assess the effect of baseline proteinuria and treatment with enalapril on the risk of first hospitalization for CHF and total mort a l i t y. Age, sex, NYHA class, ejection fraction, cardiothoracic ratio, diabetes status, and systolic blood pre s s u re were also included in the re g ression model. The Cox pro p o rtional hazards model was also used to assess the effect of ACE inhibitors on the incidence of proteinuria after adjusting for other covariates (age, sex, NYHA class, systolic blood pre s s u re, and history of diabetes). Results are presented as point estimates of relative risk (RR) (95% CI) and two-sided P v a l u e s . R E S U LT S -Of the 6,797 patients in the combined SOLVD trials, 5,487 (81%) had a re c o rded urine protein dipstick re s u l t at baseline. Baseline characteristics of this s u b g roup were similar to the SOLVD study population as a whole (data not shown).
A total of 177 patients (3.2%) had clinical proteinuria at baseline. Patients with p roteinuria had significantly higher systolic (137 vs. 125 mmHg, P 0.001) and diastolic (83 vs. 77 mmHg, P 0.001) blood p re s s u re levels, a higher prevalence of diabetes (41 vs. 18%, P 0.001), a lower ejection fraction (26.2 vs. 27.3%, P 0.05), and a worse degree of CHF (NYHA class III/IV in 22 vs. 10%, P 0.001) at baseline compared with patients without baseline proteinuria (Table 1) .
To assess the effect of ACE inhibitors on the development of clinical proteinuria, an analysis of data from patients without proteinuria at baseline was perf o rmed. Significant independent predictors of the development of clinical proteinuria were NYHA class (RR 3.33 [1.94-5.69], P = 0.0001 for NYHA class III/IV vs. NYHA class I/II) and systolic blood pre s s u re (1.2 [1.1-1.3], P = 0.003 per 10 mmHg incre a s e ) . A significant interaction was evident between treatment assignment and diabetes status, which indicates a diff e rential effect of enalapril on the development of pro t e i n u r i a in patients with and without diabetes (P = 0.007) ( Table 2) . Among 970 diabetic patients without baseline proteinuria, the RR of developing proteinuria over 2 years in patients assigned to enalapril was 0.38 (0.17-0.81) (P = 0.0123) compared with those assigned to placebo. Enalapril did not reduce the risk of developing proteinuria in 4 ,3 35 non diabetic pati en ts (1.43 [0.77-2.63], P = 0.2622) ( Table 3) .
The prognosis of patients with baseline p roteinuria was also assessed by using Cox re g ression models. These patients had a 1.81-fold (1.37-2.41) increased risk of hospitalization for CHF and a 1.73-fold (1.34-2.24) increased risk of mort a l i t y c o m p a red with patients without baseline p roteinuria after adjusting for age, sex, NYHA class, diabetes status, card i o t h o r a c i c ratio, ejection fraction, and tre a t m e n t assignment (Table 4) . A significant interaction was evident between treatment and diabetes status re g a rding the risk of hospitalization for CHF, which indicates that the e ffect of enalapril was diff e rent in diabetic and nondiabetic patients. In this model, diabetic patients taking placebo were 2.17 times more likely to be hospitalized for CHF compared with diabetic patients assigned to enalapril (1.30-3.67); the corresponding RR in nondiabetic patients taking placebo was 1.60 (1.34-1.84).
C O N C L U S I O N S -Enalapril pre-
vented clinical proteinuria for 2 years in diabetic patients without proteinuria at baseline in the SOLVD studies. The f i n d i n g s f rom this reanalysis of a large double-blind p l a c e b o -c o n t rolled study are c o n s i s t e n t with an earlier blinded randomized trial that showed that ACE inhibitors delay prog ression from microalbuminuria to m a c roalbuminuria in patients with type 2 diabetes (11). Our findings are also consistent with other single-blind trials (12) and with several blinded and open studies of ACE inhibitors in patients with type 1 diabetes (13-18). More o v e r, this reanalysis of a completed clinical trial provides the first data to show that ACE inhibitors pre v e n t p roteinuria in diabetic patients with LV d y s f u n c t i o n .
Enalapril did not prevent pro t e i n u r i a in nondiabetic patients in the SOLVD. This may reflect insufficient power to detect even a moderate effect of enalapril on albuminuria in this subgroup given the very low incidence (1%) of clinical pro t e i n u r i a in nondiabetic patients in the SOLV D . M o re o v e r, the basic mechanisms of nondiabetic nephropathies are diff e rent fro m those operating in diabetic nephro p a t h y (19), and ACE inhibitors may not be re n op rotective in all patients with nondiabetic n e p h ropathies (20). Although ACE inhibitors have been shown to reduce the ,22) , the ability of ACE inhibitors to prevent the p ro g ression of microalbuminuria to clinical proteinuria in nondiabetic patients has not been studied. Enalapril also reduced the risk of hospitalization for CHF in patients in whom p roteinuria was measured at baseline. M o re o v e r, treatment with enalapril re s u l t e d in a greater reduction in the risk of hospitalization for CHF in diabetic patients than in nondiabetic patients after adjusting for potential confounders. This result diff e r s f rom that of a previous analysis of the S O LVD, in which no interaction was evident between diabetes and tre a t m e n t re g a rding the risk of hospitalization for CHF (23) . This discrepancy re s u l t e d because our analysis adjusted for baseline p roteinuria status, whereas the pre v i o u s analysis did not. Indeed, when we deleted baseline proteinuria status from our analysis, the re g ression coefficient (i.e., estimated log RR) of the interaction between diabetes and treatment decreased by 42.4% and was no longer significant (P = 0.166). Baseline proteinuria status may t h e re f o re affect the relationship between diabetes and treatment re g a rding the risk of hospitalization for CHF.
Baseline clinical proteinuria was associated with other cardiovascular risk factors (higher blood pre s s u re and diabetes) and worse functional status in patients with LV dysfunction in the SOLVD. This confirm s p revious observations of an association between proteinuria and card i o v a s c u l a r risk factors (3) or higher NYHA class (24). Clinical proteinuria has been pre v i o u s l y shown to increase the risk of mortality in unselected populations of patients with and without diabetes (2,4,5). This is the first study to suggest that clinical proteinuria is also a risk factor for mortality in patients with LV dysfunction.
In conclusion, clinical proteinuria was p resent in a small number of patients with symptomatic and asymptomatic LV dysfunction in the SOLVD and was associated with diabetes, higher blood pre s s u re, worse h e a rt failure, and a higher risk of hospitalization for CHF and mort a l i t y. Assignment to enalapril reduced the risk of developing clinical proteinuria in diabetic patients without proteinuria at baseline. Confirm ation of these findings in a broader group of high-risk middle-aged diabetic patients and an exploration of the relationship between the decrease in albuminuria with ACE inhibitors and the incidence of card i o v a scular events should be forthcoming fro m ongoing studies such as the MICRO-HOPE ( M i c rovascular Cardiovascular Renal Outcomes in the HOPE Trial) substudy of the H O P E ( H e a rt Outcomes Prevention Evaluation) Study (25) . 
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